Interviews

Jay Lichter

President & CEO

Arialys Therapeutics

2024-05-08

Our research was recognized as a top presentation among hundreds at a major neuropsychopharmacology conference.

Arna Ionescu Stoll

CEO

Wavely Diagnostics

2024-05-08

The future for Wavely Diagnostics involves expanding our diagnostic capabilities. The digital diagnostics market is ripe for integration, with many companies currently operating in silos.

Jane Chung

President & COO

Sutro Biopharma

2024-05-08

What sets Sutro apart is our cell-free drug design process, allowing us to introduce non-natural amino acids and create ADCs with higher potencies and dual payloads.

A. Lake Wooten Ph.D

Site Director – ATLab Indianapolis

Orano Med

2024-05-07

Our leading drug candidate, AlphaMedix, developed in partnership with Radiomedix, targets neuroendocrine tumors using lead-212 and is similar in structure to Novartis's FDA-approved Lutathera.

Chris Molloy

University Professor, Chancellor Emeritus

Rutgers University

2024-05-03

The ever increasing understanding of the body’s immune system capacity to heal as well as our symbiotic relationship with microorganisms (our microbiome) continue to provide profound insights that have reshaped my view of health and disease.

Robert Califf

Commissioner

The Food and Drug Administration (FDA)

2024-05-03

Building on some of the lessons learned during the COVID-19 pandemic such as the benefits of enhanced communication and global regulatory collaboration, the FDA is committed to helping facilitate the development and approval of safe and effective treatments for patients with serious and rare diseases, especially when the product is the first available treatment - or if it has advantages over existing treatments.

Anthony Costello

CEO

Medidata

2024-05-03

Our systems are designed to balance the scientific needs of a trial with patient participation, ensuring that trials are not overly burdensome and can effectively gather necessary data without deterring enrollment.

Jodie Morgan

CEO

Nexus Circular

2024-05-03

Nexus aims to complement mechanical recycling through advanced processes by managing many of today’s plastic formats, such as films, flexible packaging and foams, which often end in landfills. This approach addresses the limitations of current recycling methods, improving the overall recycling ecosystem and with it, the perception of plastics and plastics recycling.

David Kirn

Co-Founder & CEO

4D Molecular Therapeutics

2024-05-03

At 4DMT, we applied this concept to the capsid of Adeno-Associated Virus (AAV) for gene delivery. Our process starts by generating roughly a billion different capsid versions, then selecting the most effective for targeting specific cells and tissues by a preferred method of administration.

Jason Gorevic

CEO

Teladoc Health

2024-05-03

Teladoc Health aimed to increase healthcare system capacity by leveraging underutilized physician time and overcoming location barriers.

Pagina 55 din 154